Gabriel Morris
Financieel Directeur/CFO bij IMMIX BIOPHARMA, INC.
Vermogen: 1 M $ op 30-04-2024
Actieve functies van Gabriel Morris
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
IMMIX BIOPHARMA, INC. | Directeur/Bestuurslid | 01-03-2021 | - |
Financieel Directeur/CFO | 01-03-2021 | - | |
Investor Relations Contact | 01-03-2021 | - | |
Alwaysraise LLC | Corporate Officer/Principal | 01-01-2020 | - |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | President | - | - |
Loopbaan van Gabriel Morris
Eerdere bekende functies van Gabriel Morris
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Operationeel Directeur | - | 03-01-2021 |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Financieel Directeur/CFO | 01-01-2019 | 01-01-2020 |
Opleiding van Gabriel Morris
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Operationeel
Director of Finance/CFO | 2 |
Director/Board Member | 1 |
Investor Relations Contact | 1 |
Sectoraal
Health Technology | 3 |
Consumer Services | 2 |
Technology Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Alwaysraise LLC | |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Technology Services |
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Finance |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Beurs
- Insiders
- Gabriel Morris
- Ervaring